Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

Outcome in schizophrenia: beyond symptom reduction.

Meltzer HY.

J Clin Psychiatry. 1999;60 Suppl 3:3-7; discussion 8. Review.

2.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

3.

Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.

Stargardt T, Weinbrenner S, Busse R, Juckel G, Gericke CA.

J Ment Health Policy Econ. 2008 Jun;11(2):89-97.

PMID:
18509216
4.

Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals.

Essock SM, Frisman LK, Covell NH, Hargreaves WA.

Arch Gen Psychiatry. 2000 Oct;57(10):987-94.

PMID:
11015817
5.

[Medico-economic study of Léponex (clozapine) in the Bordeaux Charles Perrens Hospital Center].

Bret P, Jolivel C, Bret MC, Veylit S, Martin C, Garcia P.

Encephale. 1998 Jul-Aug;24(4):365-77. French.

PMID:
9809242
6.

The effects of clozapine on cognitive functioning in schizophrenia.

McGurk SR.

J Clin Psychiatry. 1999;60 Suppl 12:24-9. Review.

7.

Impact of atypical antipsychotics on quality of life in patients with schizophrenia.

Awad AG, Voruganti LN.

CNS Drugs. 2004;18(13):877-93. Review.

PMID:
15521791
8.

New vs. old antipsychotics: the Texas experience.

Reid WH.

J Clin Psychiatry. 1999;60 Suppl 1:23-5; discussion 28-30.

10.

Annual health outcomes and treatment costs for schizophrenia populations.

Mauskopf JA, David K, Grainger DL, Gibson PJ.

J Clin Psychiatry. 1999;60 Suppl 19:14-9; discussion 20-2.

11.

New antipsychotic agents: emerging clinical profiles.

Buckley PF.

J Clin Psychiatry. 1999;60 Suppl 1:12-7; discussion 28-30. Review.

12.

Atypical antipsychotics in the managed care era.

Loebel AD, Botts SR, Feldman BI.

Am J Manag Care. 1998 Jan;4 Suppl:S37-50; quiz S51-2.

13.

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW.

Arch Gen Psychiatry. 2006 Oct;63(10):1079-87.

PMID:
17015810
14.
16.

[Medico-economic evaluation of treatment with clozapine versus treatment with previous neuroleptics].

Geronimi-Ferret D, Lesay M, Barges-Bertocchio MH, Cornet-Bonnefont M, Robert H.

Encephale. 1997 Sep;23 Spec No 4:24-31. French.

PMID:
9417402
17.

Should clozapine continue to be restricted to third-line status for schizophrenia?: a decision-analytic model.

Wang PS, Ganz DA, Benner JS, Glynn RJ, Avorn J.

J Ment Health Policy Econ. 2004 Jun;7(2):77-85.

PMID:
15208468
18.

Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

Rosenheck R, Cramer J, Allan E, Erdos J, Frisman LK, Xu W, Thomas J, Henderson W, Charney D.

Arch Gen Psychiatry. 1999 Jun;56(6):565-72.

PMID:
10359474
19.

Treatment-resistant schizophrenia: reviewing the options and identifying the way forward.

Hellewell JS.

J Clin Psychiatry. 1999;60 Suppl 23:14-9. Review.

20.

[Costs of treatment in patients with schizophrenia switched to amisulpride--one-year follow-up].

Harangozó J, Slezák A, Borsos K, Németh O, Csukly G.

Psychiatr Hung. 2008;23(6):464-71. Hungarian.

PMID:
19218628

Supplemental Content

Support Center